mRNA Vaccines in the COVID-19 Pandemic: Production, Antibody Formation Mechanism and Advantages of mRNA Vaccines

Marsya Naranissa Puteri Santoso; Hasna Labib Lathiefah; Fadly Hidayaturochman

doi:10.63142/ijeti.v1i1.240

Authors

Marsya Naranissa Puteri Santoso Universitas Muhammadiyah Bandung Author
Hasna Labib Lathiefah Universitas Muhammadiyah Bandung Author
Fadly Hidayaturochman Universitas Muhammadiyah Bandung Author

DOI:

https://doi.org/10.63142/ijeti.v1i1.240

Keywords:

Antibody, mRNA, Vaccine

Abstract

Vaccines are antigens that are inactivated or attenuated to produce biological products that can stimulate the immune system. The mRNA vaccine is a new type of vaccine in an effort to deal with the coronavirus disease outbreak. An mRNA vaccine is a vaccine that carries the genetic information of a pathogen that is copied in mRNA This literature review uses an online-based literature study, the library sources selected for use are based on relevance to the topic. The stages of vaccine production include sequence cloning, purification, addition of cap structures, in the delivery of mRNA vaccines formulated in the form of lipid nanoparticles. mRNA vaccines are injected intramuscularly which will then trigger immune cells so that adaptive immune cells are formed. mRNA vaccines can be designed to synthesize quickly, mRNA vaccines do not interfere with cellular function or integrate into the host genome.

Author Biographies

Marsya Naranissa Puteri Santoso, Universitas Muhammadiyah Bandung

Universitas Muhammadiyah Bandung
Hasna Labib Lathiefah, Universitas Muhammadiyah Bandung

Universitas Muhammadiyah Bandung
Fadly Hidayaturochman, Universitas Muhammadiyah Bandung

Universitas Muhammadiyah Bandung

References

Khariri, “Perjalanan Panjang Dalam Pengembangan Vaksin Baru,” SEMINAR NASIONAL RISET KEDOKTERAN (SENSORIK), pp. 128-134, 2022.

T. G. &. G. V. Borkar, “Techniques Employed in Production of Traditional Vaccines Commonly used by Military Forces: A Review,” J Arch Mil Med, pp. 2-12, 2019.

Efriza, “COVID-19,” BRMJ: Baiturrahman Medical Journal, pp. 1(1):61-68, 2021.

E. Parwanto, “Virus Corona (SARS-CoV-2) Penyebab COVID-19 kini telah bermutasi,” Jurnal Biomedika dan Kesehatan, pp. 4(2):47-49, 2021.

D. Suzana, “Mekanisme Kerja Vaksin mRNA Untuk Meningkatkan Imunitas Tubuh Terhadap Virus SARS-CoV-2,” Jurnal Kewarganegaraan, pp. 6(2): 4114-4130, 2022.

L.-A. Y. C. G. J. N. K. &. P. N. Wong, “COVID-19 Vaccine: Review of the Mechanism of Action of Different Types of Vaccine.,” Open Access Library Journal,, pp. 1-20, 2022.

R. J. Cox dan K. A. Brokstad, “Not just antibodies: B cells and T cells mediate immunity to COVID-19,” Nature Reviews Immunology, pp. 581-582, 2020.

F. X. Heinz dan K. Stiasny, “Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action,” nature partner journals , pp. 1-13, 2021.

Rosa, Prazeres, Azevedo dan Marques, “mRNA vaccines manufacturing: challenges and bottlenecks,” Vaccine, vol. 39, no. 16, pp. 2190-2200, 2021.

L. A. A. E. J. R. N. G. R. P. C. M. M. C. R. N. M. M. P. C. J. D. D. M. R. S. L. J. P. A. J. M. A. F. B. D.-R. N. A. C. K. S. M. K. M. Jackson, “An mRNA vaccine against SARS-CoV-2 — Preliminary report,” New England Journal of Medicine, vol. 383, no. 20, pp. 1920-1931, 2020.

S. K. Niazi, “ Making COVID-19 mRNA vaccines accessible: challenges resolved,” Expert Review of Vaccines, vol. 21, no. 9, p. 1163–1176, 2022.

Pardi, Hogan, Porter dan Weissman, “mRNA vaccines-a new era in vaccinology,” Nature Reviews Drug Discovery, vol. 17, no. 4, pp. 261-179, 2018.

T. Mascelino, F. Timoteo, Di, D. Angelis dan A. Oliva, “Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety,” pp. 3459-3476, 2021.

Suzana, Melina, Endrati, Ninia dan Qothoni, “Mekanisme kerja vaksin mRNA untuk meningkatkan imunitas tubuh terhadap virus SARS-CoV-2,” Jurnal Kewarganegaraan, vol. 6, no. 2, pp. 4114-4130, 2022.

Meo, Bukhari, Akram, Meo dan Klonoff, “COVID-19 vaciness: Comparison og biological , pharmacological charachteristics and adverse effect of pfizer/BioNTech and moderna vaccines,” European Review for Medical and Pharmacological, vol. 25, no. 3, pp. 1662-1679, 2021.

Zost, Gilchuk, Chen, Case, Reidy, Trivette, Nargi, Sutton, Suryadevara, Chen dan Binsthein, “Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein,” Nature Medicine, vol. 26, no. 9, pp. 1422-1427, 2020.

Corbett, Flynn, Flouds, Francica, Wernwe, Flach, Bock, Minai , Nagata dan Andersen, “Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates,” New England Journal of Medicine, vol. 383, no. 16, pp. 1544-1555, 2020.

M. Uddin dan M. Roni, “Challenges of storage and stability of mRNA-based COVID-19 vaccines,” Vaccines, vol. 9, p. 1033, 2021.

Litvinova, Rudometov, Karpenko dan Ilyichev, “mRNA vaccine platform: mRNA production and delivery,” Rusian Journal of Bioorganic Chemistry, vol. 49, pp. 220-235, 2023.

Zhu, Li, Guan, Hou, Wang, Li, Wu, Wang dan Sen, “Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, nonrandomised, first-in-human trial,” The Lancet, vol. 395, no. 10240, pp. 1845-1854, 2020.

J. Ulmer dan A. Geall, “Recent innovations in mRNA vaccines,” Current Opinion in Immunology, vol. 41, pp. 18-22, 2016.

Hoffman, Kleine-Weber, Schroeder, Kruger, Herrler, Erichsen, Schiergen, Herrler dan Wu, “SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor,” CELL, vol. 181, no. 2, pp. 271-280, 2020.